Correction to: Neuropsychopharmacology advance online publication 22 August 2007; doi:10.1038/sj.npp.1301531
Following the online publication of this article, the authors have provided the following affiliation corrections: Dr Louise Levine retired from Eli Lilly and Co.; she is not affiliated with Merck and Co. When this study was conducted, she and all other authors were employees of Eli Lilly and Co.’
Additional information
The online version of the original article can be found at 10.1038/sj.npp.1301531
Rights and permissions
About this article
Cite this article
Dunayevich, E., Erickson, J., Levine, L. et al. Erratum: Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder. Neuropsychopharmacol 33, 2549 (2008). https://doi.org/10.1038/sj.npp.1301622
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.npp.1301622
